✦ LIBER ✦

Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: A randomized, multicenter, open-label phase 1 study

✍ Scribed by Manitpisitkul, Prasarn; Shalayda, Kevin; Todd, Mike; Wang, Shean S.; Ness, Seth; Ford, Lisa

Book ID: 119828351
Publisher: Wiley (Blackwell Publishing)
Year: 2012
Tongue: English
Weight: 283 KB
Volume: 54
Category: Article
ISSN: 0013-9580
DOI: 10.1111/epi.12019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of eslicarbazepine a

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study

✍ Christian Elger; Peter Halász; Joana Maia; Luis Almeida; Patrício Soares-da-Silv 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 337 KB

Adjunctive levetiracetam in patients age

Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: Subpopulation analysis of a prospective, open-label extension study of up to 48 weeks

✍ Jesus Eric Piña-Garza; Jimmy Schiemann-Delgado; Haichen Yang; Benjamin Duncan; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Long-term safety and efficacy of eslicar

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study

✍ Hufnagel, Andreas; Ben-Menachem, Elinor; Gabbai, Alberto A.; Falcão, Amílcar; Al 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 389 KB

Long-term efficacy and safety of eslicar

Long-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy

✍ Peter Halász; Joyce A. Cramer; Danilo Hodoba; Anna Członkowska; Alla Guekht; Joa 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 300 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB